Objective To investigate the efficacy of hydroxychloroquine(HCQ)combined with angiotensin-converting enzyme inhibitor(ACEI)in the treatment of children with non-massive pro-teinuria IgA vasculitis nephritis(IgAVN).Methods A total of 42 children with non-massive pro-teinuria IgAVN in the Guiyang Maternal and Child Healthcare Hospital from August 2023 to August 2024 were collected as the study subjects.They were divided into ACEI group(n=23)and ACEI combined with HCQ group(n=19).The urinary microalbumin level,24-hour urinary protein,rou-tine urinalysis,adverse reactions,electrocardiogram findings,and fundus examination results were compared between the two groups before and after treatment.Results At 0.5,1,3 and 6 months of treatment,the urinary microalbumin,24-hour urinary protein,and urinary red blood cell counts in both groups showed significantly decreasing trend(P＜0.05).At 3 and 6 months of treatment,the urinary microalbumin and 24-hour urinary protein levels in the ACEI combined with HCQ group were significantly lower than those in the ACEI group(P＜0.05).At 0.5,1,3,and 6 months of treat-ment,the urinary red blood cell counts in the ACEI combined with HCQ group were significantly lower than those in the ACEI group(P＜0.05).The total remission rate was 68.4％(13/19)in the ACEI combined with HCQ group and 56.5％(13/23)in the ACEI group,with no significant between-group difference(P＞0.05).In the ACEI combined with HCQ group,there were 2 cases of nausea,1 case of abnormal liver function,and 1 case of respiratory tract infection,with a total incidence rate of 21.1％(4/19).In the ACEI group,there were 2 cases of nausea,2 cases of diz-ziness,1 case of abnormal liver function,and 2 cases of respiratory tract infection,with a total inci-dence rate of 30.4％(7/23).There was significant difference in the total incidence of adverse re-actions between the two groups(P=0.029).No serious adverse events such as arrhythmia or reti-nopathy occurred in children in the two groups.Conclusion HCQ combined with ACEI treatment exhibits a favorable anti-urinary protein effect and good safety.

Objective To evaluate the effectiveness and safety of Shuangyi Qushi Tongluo Capsules ( SQTC) in treating ankylosing spondylitis (AS), and to explore the synergistic action of SQTC combined with sulfasalazine. Methods A randomized and parallel-controlled trial was carried out in 80 AS patients. The enrolled subjects were evenly randomized into testing group and control group. Both groups were given oral use of sulfasalazine enteric-coated tablets, and the testing group was additionally given oral use of SQTC, which is mainly composed of silky ant (Formica Fusca), black-winged Termitidae, Scorpio, Radix Ginseng, Radix Astragali, Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Flos Carthami, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Caulis Spatholobi, Herba Epimedii, and Radix Morindae Officinalis. The treatment for the two groups covered 24 weeks. On treatment week 4, 12, 24, we recorded the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), visual analog scale (VAS) scores of rachialgia, patients’ general assessment (PGA), VAS scores of night pain, spondylitis scores, Bath Ankylosing Spondylitis Functional Index ( BASFI) , Bath Ankylosing Spondylitis Metrology Index ( BASMI) , scores of the quality of life ( QOL) , erythrocyte sedimentation rate ( ESR) , C-reactive protein ( CRP). Moreover, the adverse reaction of the two groups was also monitored. Results ( 1) Compared with the control group, testing group had high ASAS 20 percentage on treatment week 4, 12 and 24 (P<0.05 or P<0.01). (2) After treatment for 12, 24 weeks, the observation indexes were much improved in the testing group ( P<0.05 or P<0.01 compared with the control group). ( 3) In the control group, one case ( 2.86%) had slight abnormal hepatic function, and one case (2.63%) in the testing group had slight gastrointestinal discomfort, the difference being insignificant (P>0.05). Conclusion SQTC are effective and safe in treating AS, starting an effect shortly and having synergistic effect on salfasalazine for the treatment of AS.

Objective To obtain differentiated osteoblast-specific inactivation of fgfr1 mice Methods To obtain fgfr1△/+/OC-CreTG/+ mice,fgfr1flox/flox mice obtained from NIH were crossed with OC-Cre mice To obtain fgfr1△/△/OC-CreTG/+ mutant mice,fgfr1△/+/OC-CreTG/+ further crossed with themselves or fgfr1flox/flox mice After fgfr1△/△/OC-CreTG/+ crossed with fgfr1flox/flox mice,half of their offspring were mutant mice Results Differentiated osteoblast-specific fgfr1 knockout mice were obtained Conclusion fgfr1△/△/OC-CreTG/+ mice were obtained through proper crossing strategy,which provides a suitable platform for studying fgfr1 function in bone development and fracture healing